We are live on
!
Find out more
ACM
Atika Capital Management Portfolio holdings
AUM
$796M
1-Year Est. Return
167.57%
This Fund
S&P 500
This Quarter
Est. Return
+15.85%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$285M
AUM Growth
+$81.2M
(+40%)
Cap. Flow
+$62.5M
Cap. Flow
% of AUM
21.89%
Top 10 Holdings %
Top 10 Hldgs %
40.02%
Holding
95
New
33
Increased
14
Reduced
26
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
American Airlines Group
AAL
|
+$5.63M |
| 2 |
Align Technology
ALGN
|
+$5.29M |
| 3 |
Take-Two Interactive
TTWO
|
+$5.13M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$5.08M |
| 5 |
Liberty Media Series C
FWONK
|
+$4.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVRO
NEVRO CORP.
NVRO
|
+$6.3M |
| 2 |
Incyte
INCY
|
+$4.81M |
| 3 |
AGN
Allergan plc
AGN
|
+$4.66M |
| 4 |
Glaukos
GKOS
|
+$3.02M |
| 5 |
United Airlines
UAL
|
+$2.92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.33% |
| 2 | Technology | 16.3% |
| 3 | Communication Services | 13.78% |
| 4 | Consumer Discretionary | 5.9% |
| 5 | Materials | 4.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SIEN
51
DELISTED
Sientra, Inc.
SIEN
| $2.14M | 0.75% |
22,000
-3,000
| -12% | -$245K |
|
52
CALL
Bausch Health
BHC
$1.67B
| $2.08M | 0.73% |
+120,000
| New | +$1.44M |
|
|
TSRO
53
DELISTED
TESARO, Inc.
TSRO
| $2.03M | 0.71% |
14,500
-13,500
| -48% | -$1.95M |
|
54
Inogen
INGN
$174M
| $2M | 0.7% |
+21,000
| New | +$1.79M |
|
|
TLND
55
DELISTED
Talend S.A. American Depositary Shares
TLND
| $1.74M | 0.61% |
+50,000
| New | +$1.63M |
|
56
Ironwood Pharmaceuticals
IRWD
$606M
| $1.7M | 0.6% |
+107,460
| New | +$1.56M |
|
57
Cognex
CGNX
$9.6B
| $1.7M | 0.59% |
+40,000
| New | +$1.78M |
|
|
SIOX
58
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $1.62M | 0.57% |
8,750
+6,000
| +218% | +$1.05M |
|
|
NDRM
59
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $1.61M | 0.57% |
+54,000
| New | +$1.4M |
|
60
Exelixis
EXEL
$14B
| $1.6M | 0.56% |
65,000
-10,000
| -13% | -$212K |
|
61
EPAM Systems
EPAM
$5.48B
| $1.6M | 0.56% |
19,000
-13,000
| -41% | -$1.04M |
|
|
OTIC
62
DELISTED
Otonomy, Inc.
OTIC
| $1.58M | 0.55% |
+84,000
| New | +$1.17M |
|
|
LKFT
63
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $1.38M | 0.48% |
18,000
-7,800
| -30% | -$656K |
|
64
Alkermes
ALKS
$8.24B
| $1.22M | 0.43% |
21,000
-1,000
| -5% | -$58.1K |
|
|
GIMO
65
DELISTED
Gigamon Inc.
GIMO
| $1.18M | 0.41% |
+30,000
| New | +$1.13M |
|
|
DOOR
66
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $1.13M | 0.4% |
15,000
-29,400
| -66% | -$2.26M |
|
67
Heron Therapeutics
HRTX
$91.6M
| $1.08M | 0.38% |
78,000
-17,000
| -18% | -$246K |
|
|
TSRO
68
CALL
DELISTED
TESARO, Inc.
TSRO
| $937K | 0.33% |
6,700
| – | – |
|
|
FINL
69
PUT
DELISTED
Finish Line
FINL
| $902K | 0.32% |
+63,700
| New | +$924K |
|
|
SLCA
70
CALL
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $869K | 0.3% |
+24,500
| New | +$965K |
|
|
71
CALL
Heron Therapeutics
HRTX
$91.6M
| $831K | 0.29% |
+60,000
| New | +$869K |
|
72
CALL
TripAdvisor
TRIP
$1.72B
| $764K | 0.27% |
20,000
| – | – |
|
|
73
CALL
Ironwood Pharmaceuticals
IRWD
$606M
| $755K | 0.26% |
+47,760
| New | +$694K |
|
|
74
Glaukos
GKOS
$9.06B
| $746K | 0.26% |
18,000
-70,000
| -80% | -$3.02M |
|
|
SAGE
75
DELISTED
Sage Therapeutics
SAGE
| $557K | 0.2% |
7,000
-2,000
| -22% | -$145K |
|
Similar funds
AGA
RIM
ACM
CAM
LSA
GWA
HP
Atika Capital Management's Q2 2017 Portfolio in Review
As of Q2 2017, Atika Capital Management held 95 positions worth $285M, up 40% from $204M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Atika Capital Management deployed $62.5M of net new capital in Q2 2017, opening 33 new positions and adding to 14 existing holdings. Its largest new stake was American Airlines Group: 121,000 shares worth $6.09M.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 36% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Glaukos, an estimated $3.02M trimmed.
- Atika Capital Management's largest Q2 2017 buy was American Airlines Group: 121,000 shares worth $6.09M.
- Atika Capital Management added most to Align Technology in Q2 2017, an estimated $5.29M increase.
- Atika Capital Management's biggest Q2 2017 reduction was Glaukos, cutting an estimated $3.02M.
- Atika Capital Management fully exited NEVRO CORP. in Q2 2017, selling an estimated $6.3M.
- Atika Capital Management's ten largest holdings make up 40% of its $285M portfolio in Q2 2017.
- Atika Capital Management opened 33 new positions and closed 19 in Q2 2017.
- Atika Capital Management's portfolio value rose 40% quarter-over-quarter to $285M.
Based on Atika Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.